{"id":3864,"date":"2000-09-16T21:50:56","date_gmt":"2000-09-16T20:50:56","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=3864"},"modified":"2014-07-01T12:06:05","modified_gmt":"2014-07-01T12:06:05","slug":"abbott-expands-early-access-program-for-abt-378r-kaletra","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/3864","title":{"rendered":"Abbott expands early-access program for ABT-378\/r (Kaletra)"},"content":{"rendered":"<p><strong>Abbott Laboratories have announced that more HIV-positive patients will now have access to its investigational protease inhibitor Kaletra (lopinavir\/ritonavir) via the company&#8217;s Early Access Program.<\/strong><\/p>\n<p>The company, based in Abbott Park, Ill, relaxed the criteria that HIV-positive patients must meet to receive Kaletra, formerly ABT-378\/r. The drug will now be available to any HIV-positive patient who needs it to &#8220;construct a viable regimen, without CD4 cell count or viral load restrictions,&#8221; Abbott said in a news release.<\/p>\n<p>Because of a limited supply of the drug, which is currently in phase III trials, Abbott&#8217;s Early Access Program was previously open only to patients with HIV who met select entry criteria.<\/p>\n<p>Developed in cooperation with key regulatory agencies and HIV advocacy groups, Abbott&#8217;s Kaletra Early Access Program operates in 21 countries worldwide and has enrolled 6100 patients with advanced HIV.<\/p>\n<h3>Comment<\/h3>\n<p><strong>Some UK physicians are still unaware that ABT-378 is available on named patient and open access studies. Interested physicians should contact Abbott in the UK on: 01628 644 370.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Abbott Laboratories have announced that more HIV-positive patients will now have access to its investigational protease inhibitor Kaletra (lopinavir\/ritonavir) via the company&#8217;s Early Access Program. The company, based in Abbott Park, Ill, relaxed the criteria that HIV-positive patients must meet &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-3864","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/3864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=3864"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/3864\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=3864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=3864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=3864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}